| CAS NO. |
Products Name |
|
|
|
|
| 1110813-31-4 |
Dacomitinib (PF299804, PF299) |
more... |
| PF-299804 is a potent, irreversible pan-ErbB inhibitor, mostly to EGFR with IC50 of 6 nM, effective against NSCLCs with EGFR or ERBB2 mutations (resistant to gefitinib) as well as those harboring the EGFR T790M mutation. Phase 2. |
|
| 1009298-59-2 |
AZD2014 |
more... |
| AZD2014 is a novel mTOR inhibitor with IC50 of 2.8 nM; highly selective against multiple PI3K isoforms (α/β/γ/δ). Phase 2. |
|
| 956104-40-8 |
ARN-509 |
more... |
| ARN-509 is a selective and competitive androgen receptor inhibitor with IC50 of 16 nM, useful for prostate cancer treatment. Phase 3. |
|
| 1260141-27-2 |
TAK438 |
more... |
| TAK-438 is a novel P-CAB (potassium-competitive acid blocker) that reversibly inhibits H+/K+, ATPase with IC50 of 19 nM (pH 6.5), controls gastric acid secretion. Phase 3. |
|
|
|
| 927880-90-8 |
RAF265 (CHIR-265) |
more... |
| RAF265 (CHIR-265) is a potent selective inhibitor of C-Raf/B-Raf/B-Raf V600E with IC50 of 3-60 nM, and exhibits potent inhibition on VEGFR2 phosphorylation with EC50 of 30 nM. Phase 2. |
|
|
|
| 896466-04-9 |
AT9283 |
more... |
| AT9283 is a potent JAK2/3 inhibitor with IC50 of 1.2 nM/1.1 nM; also potent to Aurora A/B, Abl(T315I). Phase 2. |
|
|
|
| 936727-05-8 |
VX809 |
more... |
| VX-809 (Lumacaftor) acts to correct CFTR mutations common in cystic fibrosis by increasing mutant CFTR (F508del-CFTR) maturation,EC50 of 0.1 μM. Phase 3. |
|
All Products
